Methyl Testosterone 25mg/tab 100 Tabletten by Kim Pharma

Usage

1. Run a full metabolic blood panel — fasting glucose, HbA1c, ALT, AST, total cholesterol — at least 7 days before the first tablet to establish your personal baseline values.
2. Take each 25 mg tablet with a mixed macronutrient meal; administering the dose alongside dietary carbohydrates allows monitoring of any post-prandial glucose response attributable to the compound.
3. Where the daily protocol calls for two tablets (50 mg), divide the dose morning and early afternoon — aligning peak androgen levels with the body's two highest carbohydrate-intake windows.
4. Moderate total daily carbohydrate intake to 3–4 g per kg of bodyweight during the cycle, adjusting downward if mid-cycle fasting glucose readings rise above pre-cycle baseline by more than 10 %.
5. Repeat the fasting blood glucose test at week 4 of the cycle; if glucose is elevated, reduce carbohydrate intake or shorten the cycle — do not simply ignore the data.
6. Upon cycle completion, begin PCT within 3 days and re-run the full metabolic panel at weeks 2 and 6 post-cycle to confirm that both androgenic and metabolic markers have returned to baseline.

Warnings

Frequently asked questions

Does methyltestosterone affect insulin sensitivity during a bulking cycle?

Yes — documented endocrinology data show that supraphysiological androgen exposure, including from 17α-alkylated compounds like methyltestosterone, can reduce insulin sensitivity in a dose-dependent fashion. This effect is most relevant during caloric surpluses when carbohydrate intake is elevated. Monitoring fasting blood glucose before and during cycle is a practical risk-management step rather than an optional measure.

What specific metabolic effects has methyltestosterone been documented to produce?

Documented effects include improved nitrogen retention, increased muscle protein synthesis efficiency, and alterations in glucose transporter activity — specifically GLUT4 expression in skeletal and adipose tissue. These changes collectively influence how the body partitions macronutrients between energy production and anabolic tissue deposition, making dietary carbohydrate management a relevant consideration during use.

Why is blood glucose monitoring recommended when using methyltestosterone?

Because androgen-receptor-mediated changes in GLUT4 transporter activity can impair post-prandial glucose clearance, fasting blood glucose and HbA1c readings may shift measurably within weeks of initiating a methyltestosterone protocol. Establishing a pre-cycle baseline and retesting at weeks 4 and 8 allows users to detect metabolic changes early and adjust carbohydrate intake or cycle duration accordingly.

How does the 25 mg per tablet concentration of Kim Pharma's product compare to lower-strength alternatives for dose control?

At 25 mg per tablet — the highest concentration in this product group — each Kim Pharma tablet delivers a complete, HPLC-verified dose without requiring tablet splitting. Lower-strength tablets demand splitting for comparable dosing, introducing dose variance. The intact 25 mg unit preserves the dose accuracy that makes blood glucose monitoring data meaningful and reproducible across a cycle.

Are Kim Pharma's 25 mg methyltestosterone tablets supplied in blister packs or a jar, and does packaging affect tablet integrity?

Kim Pharma supplies the 100-tablet format in a controlled-environment-packaged configuration designed to protect tablet integrity against humidity and light — two variables that can degrade oral androgenic compounds over the product's shelf life. Consistent packaging conditions directly support the HPLC-confirmed potency specification by ensuring active content remains stable from production through administration. (2) angle_used

Manufacturer

Kim Pharma's quality-assurance approach for Methyl Testosterone 25 mg/tab is organised around a single governing principle: declared concentration is an instrumental finding, not a calculated estimate. For this 25 mg per tablet specification, that principle is operationalised through HPLC chromatographic analysis of every production batch — the instrument output must confirm active content within ±5 % of the label claim before a batch is eligible for release. A second, independently generated clearance certificate covers LAL (Limulus Amebocyte Lysate) endotoxin screening, applied as a precautionary standard consistent with Kim Pharma's controlled-environment production areas, where tablet compression and encapsulation operations are conducted under particulate controls exceeding conventional oral solid-dosage requirements. GMP certification governs the process architecture within which both analytical gates operate. Neither certificate substitutes for the other; batch release requires both to be filed as separate retrievable records — the structural safeguard underpinning the Purity Tested designation on this product.